Lisa A. Newman, Robert A. Winn and John M. Carethers DOI: 10.1158/1078-0432.CCR-20-3421 Published January 2021 Abstract Coronavirus disease 2019 (COVID-19) is a novel infectious disease that has spread worldwide. In the United States, COVID-19 disproportionately affects racial and ethnic minorities, particularly African Americans, with an observed 2-fold higher rate for hospitalization and greater than 2-fold higher rate for death as compared with White Americans....
Knowing all you can about clinical trials can help you feel more certain when deciding whether to take part in one. The information in this section addresses many questions and concerns about clinical trials. It can help prepare you to discuss the pros and cons with your doctor and your family and decide whether being...
STUDY TITLE: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in adult patients with Advanced Non-Small Cell Lung Cancer (NSCLC) INDICATION: Treatment of malignancy associated weight loss or anorexia in patients with NSCLC. STUDY DRUG: Anamorelin...
By: Melissa Steele-OgusPosted: Thursday, December 10, 2020 Although radical prostatectomy remains one of the primary treatments of localized high-risk prostate cancer, biochemical progression-free survival remains lower than ideal. A study published in the Journal of Clinical Oncology compared the efficacy of radical prostatectomy versus chemohormonal therapy with androgen-deprivation therapy (ADT) plus docetaxel prior to radical prostatectomy. The...
By: JNCCN 360 StaffPosted: Friday, December 18, 2020 The U.S. Food and Drug Administration (FDA) recently approved the HER2-targeted monoclonal antibody margetuximab-cmkb (Margenza) in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer who have received at least two prior anti-HER2 regimens (one of which was for metastatic disease), according to...
By: JNCCN 360 StaffPosted: Wednesday, December 2, 2020 On December 1, the U.S. Food and Drug Administration approved the radioactive diagnostic agent gallium 68 PSMA-11 (Ga 68 PSMA-11), the first drug for PET imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Ga 68 PSMA-11 is indicated for patients with suspected prostate...
ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419) – Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer STUDY SPONSOR: Galera Therapeutics, Inc. STUDY TYPE: Supportive Care METHODOLOGY: GTI-4419-301 is a randomized, double-blind, placebo-controlled, multi-center international studyconducted to evaluate GC4419 administered IV to reduce the incidence and severity of...
Randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combo with platinum-based chemo and standard fractionation IMRT in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX). Squamous cell carcinoma of the head and neck (SCCHN) is the 6th most common cancer worldwide. More than half...
QUILT-3.055: A Phase 2b, Single-Arm, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with PD-1/PD-L1 Immune Checkpoint Inhibitors. DRUGS: N-803 (aka ALT-803) + PD-L1 t-haNK suspension for infusion This study is designed to treat multiple solid tumor cancers. This type of study is done because of how the...
A Randomized, Dose-ranging, Open-label, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg (ALOXI®) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy Not all clinical research we do here at the Gettysburg Cancer Center is specifically for...
